Drug – bio-affecting and body treating compositions – Radionuclide or intended radionuclide containing; adjuvant... – Attached to antibody or antibody fragment or immunoglobulin;...
Reexamination Certificate
2011-04-26
2011-04-26
Jones, D. L (Department: 1618)
Drug, bio-affecting and body treating compositions
Radionuclide or intended radionuclide containing; adjuvant...
Attached to antibody or antibody fragment or immunoglobulin;...
C424S001110, C424S001170, C424S001650
Reexamination Certificate
active
07931890
ABSTRACT:
The present invention is directed to methods for treating cancer wherein more than one therapeutic agent is used, with each of the therapeutic agents having different tumor-killing capabilities, and wherein the therapeutic agents are delivered to the tumor sites using combined targeting and pre-targeting methods. The methods of the present invention achieve good tumor to non-tumor ratios of the therapeutic agents, and are effective for cancer therapy.
REFERENCES:
patent: 3927193 (1975-12-01), Hansen et al.
patent: 4331647 (1982-05-01), Goldenberg
patent: 4348376 (1982-09-01), Goldenberg
patent: 4361544 (1982-11-01), Goldenberg
patent: 4444744 (1984-04-01), Goldenberg
patent: 4468457 (1984-08-01), Goldenberg et al.
patent: 4474893 (1984-10-01), Reading
patent: 4479895 (1984-10-01), Auditore-Hargreaves
patent: 4624846 (1986-11-01), Goldenberg
patent: 4818709 (1989-04-01), Primus et al.
patent: 5256395 (1993-10-01), Barbet et al.
patent: 5283342 (1994-02-01), Gustavson et al.
patent: 5420105 (1995-05-01), Gustavson
patent: 5474772 (1995-12-01), Maddock
patent: 5482698 (1996-01-01), Griffiths
patent: 5525338 (1996-06-01), Goldenberg
patent: 5736119 (1998-04-01), Goldenberg et al.
patent: 5846741 (1998-12-01), Griffiths et al.
patent: 6077499 (2000-06-01), Griffiths et al.
patent: 6361774 (2002-03-01), Griffiths et al.
patent: 7011812 (2006-03-01), Griffiths et al.
patent: 7138103 (2006-11-01), Goldenberg et al.
patent: 496074 (1992-07-01), None
patent: 3503898 (1991-08-01), None
patent: 5501543 (1993-03-01), None
patent: WO9423759 (1994-10-01), None
patent: WO9741898 (1997-11-01), None
Golub et al., Science, Oct. 15, 1999, pp. 531-537.
Dox et al, The Harper Collins Illustrated Medical Dictionary, 1993, p. 132.
Golub et al., Science, Oct. 15, 1999, pp. 531-537.
Golub, T. R., et al., “Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring” Science Mag, vol. 286, Oct. 15, 1999, pp. 531-537.
Boisferon, Marc Hillairet DE, et al., “Pretargeted Radioimmunotherapy using 131I-labelled bivalent hapten-bearing peptides” Letters in Peptide Science, 4 (1997) pp. 331-339.
Barbet, J., et al., “Radioimmunodetection of Medullary thyroid Carcinoma Using Indium-111 Bivalent Hapten and Anti-CEA X anti-DTPA-Indium Bispecific Antibody,” The Journal of Nuclear Medicine, vol. 39, No. 7, Jul. 1998, pp. 1172-1178.
Janevik-Ivanovska, E., et al., “Bivalent Hapten-Bearing Peptides Designed for Iodine-131 Pretargeted Radioimmunotherapy” Bioconjugate Chem. 1997, 8, 526-533.
Schuhmacher, Jochen, et al., “Pretargeting of human mammary carcinoma xenografts with bispecific anti-MUC1/anti-Ga chelate antibodies and immunoscintigraphy with PET” Nuclear Medicine and Biology 28 (2001) 821-828.
Gautherot, Emmunuel, et al., “Immunohistology of Carcinoembryonic antigen (CEA)-expressing Tumors Grafted in Nude Mice after Radioimmunotherapy with 131I-labeled Bivalent Hapten and Anti-CEZ x Antihapten Bispecific antibody,” Clinical Cancer Research vol. 5, 3177s-3182s, Oct. 1999 (Suppl.).
Karacay, H., “Experimental Pretargeting Studies of Cancer with a Humanized anti-CEA x Murine anti-[In-DTPA] Bispecific Antibody Construct and a 99mTc-/188Re-Labeled Peptide” Bioconjugate Chem. 2000, 11, 842-854.
Dissous et al. “Schistosoma mansoni surface antigen defined by a rat monoclonal IgG2a” J. Immunol. 129 (5):2232-2234 (1982).
Grzych et al. “In vitro and in vivo effector function of rat IgG2a monoclonal anti-S. mansoni antibodies” J. Immunol. 129(6):2739-2743 (1982).
Kasper et al. “Purification of a major membrane protein of Toxoplasma gondii by immunoabsorption with a monoclonal antibody” J. Immunol. 130(5):2407-2412 (1983).
Kasper et al. “Isolation and characterization of a monoclonal antibody-resistant antigenic mutant of Toxoplasma gondii” J. Immunol. 129(4):1694-1699 (1982).
Polin et al. “Monoclonal Antibodies Against Microorganisms” Eur. J. Clin. Microbiol. 3(5):387-398 (1984).
Rossi et al. “Presence of maternal antibodies to human immunodeficiency virus 1 envelope glycoprotein gp120 epitopes correlates with the uninfected status of children born to seropositive mothers” Proc. Natl. Acad. Sci USA, 86:8055-8058 (1989).
Sher et al. “Specific inhibition of the morphogenesis of Trypanosoma cruzi by a monoclonal antibody” Nature 300:639-640 (1982).
Simpson et al. “Isolation and partial characterization of the tegumental outer membrane of adult Schistosoma mansoni” Parasitology 83:163-177 (1981).
Smith et al. “Passive immunization of mice against Schistosoma mansoni with an IgM monoclonal antibody” Parasitology 84:83-91 (1982).
Yoshida et al. “Hybridoma Produces Protective Antibodies Directed Against the Sporozoite Stage of Malaria Parasite” Science 207:71-73 (1980).
Zodda and Phillips “Monoclonal Antibody-Mediated Protection against Schistosoma mansoni Infection in Mice” J. Immunol. 129(6):2326-2328 (1982).
Goldenberg David M.
Griffiths Gary L.
Hansen Hans J.
Immunomedics Inc.
Jones D. L
Nakashima Richard A.
LandOfFree
Targeted combination immunotherapy of cancer and infectious... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Targeted combination immunotherapy of cancer and infectious..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Targeted combination immunotherapy of cancer and infectious... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2705366